Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 and CD22 Prime CAR-T in R/R B-Cell Lymphoma
NCT04782193Phase 2Unknown
- Sponsor
- Chongqing Precision Biotech
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19 and CD22 targeted prime CAR-T cells in B cell lymphoma, B cell acute lymphoblastic leukemia (B-ALL), sponsored by Chongqing Precision Biotech. Status: unknown.
02
Drugs
CD19 and CD22 targeted prime CAR-T cells
03
Conditions
B cell lymphomaB cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04782193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782193.